API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

Other Certificates

0

Other Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

ViaCyte Inc

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes

Details:

The acquisition of ViaCyte provides Vertex with complementary assets including VC-02, and technologies including additional human stem cell lines, intellectual property around stem cell differentiation, and GMP manufacturing facilities for cell-based therapies.

Lead Product(s): VC-02

Therapeutic Area: Endocrinology Product Name: VC-02

Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Vertex Pharmaceuticals

Deal Size: $320.0 million Upfront Cash: $320.0 million

Deal Type: Acquisition July 11, 2022

ASK
US